These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 24112768)

  • 1. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors.
    Amir I; Konikoff FM; Oppenheim M; Gophna U; Half EE
    Environ Microbiol; 2014 Sep; 16(9):2905-14. PubMed ID: 24112768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
    Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus.
    Jankowski JA; Anderson M
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():71-80; discussion 95-6. PubMed ID: 15456468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations?
    Frazzoni M; Manno M; De Micheli E; Savarino V
    Dig Liver Dis; 2006 Sep; 38(9):643-8. PubMed ID: 16627016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A non-endoscopic device to sample the oesophageal microbiota: a case-control study.
    Elliott DRF; Walker AW; O'Donovan M; Parkhill J; Fitzgerald RC
    Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):32-42. PubMed ID: 28404012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dietary inflammatory index and risk of reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma: a population-based case-control study.
    Shivappa N; Hebert JR; Anderson LA; Shrubsole MJ; Murray LJ; Getty LB; Coleman HG
    Br J Nutr; 2017 May; 117(9):1323-1331. PubMed ID: 28571591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Barrett's oesophagus, oesophageal adenocarcinoma and reflux oesophagitis and the use of nitrates and asthma medications.
    Ladanchuk TC; Johnston BT; Murray LJ; Anderson LA;
    Scand J Gastroenterol; 2010 Dec; 45(12):1397-403. PubMed ID: 20626305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oesophageal disease: gastroesophageal reflux disease, Barrett's oesophagus, achalasia and eosinophilic oesophagitis.
    Calvet X
    Gastroenterol Hepatol; 2016 Sep; 39 Suppl 1():47-52. PubMed ID: 27888864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of proton pump inhibitors in gastro-oesophageal reflux disease.
    Dekel R; Morse C; Fass R
    Drugs; 2004; 64(3):277-95. PubMed ID: 14871170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The changing spectrum of gastroesophageal reflux disease.
    Todd JA; Johnston DA; Dillon JF
    Eur J Cancer Prev; 2002 Jun; 11(3):215-9. PubMed ID: 12131654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
    Dunbar KB; Souza RF; Spechler SJ
    Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: prevalence of Barrett's oesophagus and metaplasia at the gastro-oesophageal junction.
    Sharma P
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():48-54; discussion 61-2. PubMed ID: 15456464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus.
    Koek GH; Sifrim D; Lerut T; Janssens J; Tack J
    Gut; 2008 Aug; 57(8):1056-64. PubMed ID: 18403496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease.
    Shi YC; Cai ST; Tian YP; Zhao HJ; Zhang YB; Chen J; Ren RR; Luo X; Peng LH; Sun G; Yang YS
    Genomics Proteomics Bioinformatics; 2019 Feb; 17(1):52-63. PubMed ID: 31028880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes to the upper gastrointestinal microbiotas of children with reflux oesophagitis and oesophageal metaplasia.
    Luu LDW; Singh H; Castaño-Rodríguez N; Leach ST; Riordan SM; Tedla N; Krishnan U; Kaakoush NO
    Microb Genom; 2022 Sep; 8(9):. PubMed ID: 36107142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary magnesium, calcium:magnesium ratio and risk of reflux oesophagitis, Barrett's oesophagus and oesophageal adenocarcinoma: a population-based case-control study.
    Dai Q; Cantwell MM; Murray LJ; Zheng W; Anderson LA; Coleman HG;
    Br J Nutr; 2016 Jan; 115(2):342-50. PubMed ID: 26563986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.
    Solaymani-Dodaran M; Logan RF; West J; Card T; Coupland C
    Gut; 2004 Aug; 53(8):1070-4. PubMed ID: 15247170
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.